Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 1/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904629 | 1.00 | S100B (0.70) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL2904627 | 1.00 | S100B (0.70) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL5437008 | 1.00 | S100B (0.70) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL10412841 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL2010515 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL10733285 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL12416630 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL10733277 | 0.91 | S100B (0.82) | S100BPTGS2PTGS1CA12CA2 | |
| SCHEMBL4787112 | 0.88 | S100B (0.56) | S100BNFE2L2PTGS2PTGS1CA12 | |
| SCHEMBL4787108 | 0.88 | S100B (0.56) | S100BNFE2L2PTGS2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070122341-A1 | Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-05-31 | — | — | US | disclosed |
| EP-0690856-B1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | UNIV NEW YORK STATE RES FOUND (US) | 2002-12-04 | — | — | EP | disclosed |
| US-5705508-A | FORMING TAXOL DERIVATIVES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-01-06 | — | — | US | disclosed |
| US-5599820-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0690856-A4 | — | UNIV NEW YORK (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0690856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5475011-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1994022856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122341-A1 | Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques | APP, BACE1, APBA1 | S100B 219/4885NFE2L2 546/4885PTGS2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.